Yu-Jing Qian

The dual immune landscape of homologous recombination-deficient tumors: mechanisms and therapeutic implications

Homologous recombination deficiency (HRD) is a major genomic feature of several malignancies and provides a therapeutic rationale for DNA-damaging agents and PARP inhibitors. Beyond its role in genome instability, accumulating evidence suggests that HRD also reshapes the tumor microenvironment (TME). However, the immun...